WallStreetZenWallStreetZen

NASDAQ: IMPL
Impel Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

IMPL past revenue growth

How has IMPL's revenue growth performed historically?
Company
155.29%
Industry
112.01%
Market
13.97%
IMPL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IMPL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IMPL's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IMPL earnings and revenue history

Current Revenue
$21.0M
Current Earnings
-$74.3M
Current Profit Margin
-353.9%

IMPL Return on Equity

Current Company
N/A
Current Industry
15.6%
Current Market
-9.5%

Be the first to know when IMPL announces earnings.

IMPL Return on Assets

Current Company
-127.4%
Current Industry
2.2%
IMPL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IMPL Return on Capital Employed

Current Company
69.04%
Current Industry
17.7%

IMPL vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IMPL$20.99M-$59.42M-$74.28M+1,418.64%N/A
FRES$1.65MN/A-$17.50M+37.14%N/A
TOVX$0.00-$20.69M-$18.46MN/AN/A
GOVX$0.00-$23.69M-$23.76M-100.00%N/A
BCEL$0.00-$91.11M-$97.76MN/AN/A
View Top Biotech Stocks

Impel Pharmaceuticals Earnings & Revenue FAQ

What were IMPL's earnings last quarter?

On Invalid Date, Impel Pharmaceuticals (NASDAQ: IMPL) reported Q3 2023 earnings per share (EPS) of -$0.58, up 55.73% year over year. Total Impel Pharmaceuticals earnings for the quarter were -$13.81 million. In the same quarter last year, Impel Pharmaceuticals's earnings per share (EPS) was -$1.31.

If you're new to stock investing, here's how to buy Impel Pharmaceuticals stock.

What was IMPL's earnings growth in the past year?

As of Q4 2023, Impel Pharmaceuticals's earnings has grown year over year. Impel Pharmaceuticals's earnings in the past year totalled -$74.28 million.

What was IMPL's revenue last quarter?

On Invalid Date, Impel Pharmaceuticals (NASDAQ: IMPL) reported Q3 2023 revenue of $5.02 million up 62.98% year over year. In the same quarter last year, Impel Pharmaceuticals's revenue was $3.08 million.

What was IMPL's revenue growth in the past year?

As of Q4 2023, Impel Pharmaceuticals's revenue has grown 155.29% year over year. This is 43.28 percentage points higher than the US Biotechnology industry revenue growth rate of 112.01%. Impel Pharmaceuticals's revenue in the past year totalled $20.99 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.